A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Pre-planned IA (global study) showed lack of efficacy in this indication. No new safety signals observed, findings consistent with known profile.

Conditions

Lupus Erythematosus, Systemic

Interventions

DRUG: Ustekinumab (approximately 6 mg/kg)
DRUG: Ustekinumab 90 milligram (mg)
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC